Literature DB >> 33753152

Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay.

Matthew J Murray1, Megan McIntosh2, Claire Atkinson2, Tabitha Mahungu3, Edward Wright4, Wendy Chatterton5, Michael Gandy5, Matthew B Reeves6.   

Abstract

OBJECTIVES: To assess whether a commercially available CE-IVD, ELISA-based surrogate neutralisation assay (cPass, Genscript) provides a genuine measure of SARS-CoV-2 neutralisation by human sera, and further to establish whether measuring responses against the RBD of S was a diagnostically useful proxy for responses against the whole S protein.
METHODS: Serum samples from 30 patients were assayed for anti-NP responses, for 'neutralisation' by the surrogate neutralisation assay and for neutralisation by SARS-CoV-2 S pseudotyped virus assays utilising two target cell lines. Correlation between assays was measured using linear regression.
RESULTS: The responses observed within the surrogate neutralisation assay demonstrated an extremely strong, highly significant positive correlation with those observed in both pseudotyped virus assays.
CONCLUSIONS: The tested ELISA-based surrogate assay provides an immunologically useful measure of functional immune responses in a much quicker and highly automatable fashion. It also reinforces that detection of anti-RBD neutralising antibodies alone is a powerful measure of the capacity to neutralise viral infection.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33753152      PMCID: PMC7979278          DOI: 10.1016/j.jinf.2021.03.010

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  29 in total

1.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.

Authors:  Nina Le Bert; Anthony T Tan; Kamini Kunasegaran; Christine Y L Tham; Morteza Hafezi; Adeline Chia; Melissa Hui Yen Chng; Meiyin Lin; Nicole Tan; Martin Linster; Wan Ni Chia; Mark I-Cheng Chen; Lin-Fa Wang; Eng Eong Ooi; Shirin Kalimuddin; Paul Anantharajah Tambyah; Jenny Guek-Hong Low; Yee-Joo Tan; Antonio Bertoletti
Journal:  Nature       Date:  2020-07-15       Impact factor: 49.962

2.  Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2.

Authors:  Markus Hoffmann; Kirstin Mösbauer; Heike Hofmann-Winkler; Artur Kaul; Hannah Kleine-Weber; Nadine Krüger; Nils C Gassen; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Nature       Date:  2020-07-22       Impact factor: 49.962

3.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.

Authors:  Manli Wang; Ruiyuan Cao; Leike Zhang; Xinglou Yang; Jia Liu; Mingyue Xu; Zhengli Shi; Zhihong Hu; Wu Zhong; Gengfu Xiao
Journal:  Cell Res       Date:  2020-02-04       Impact factor: 25.617

4.  Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana.

Authors:  Kaewta Rattanapisit; Balamurugan Shanmugaraj; Suwimon Manopwisedjaroen; Priyo Budi Purwono; Konlavat Siriwattananon; Narach Khorattanakulchai; Oranicha Hanittinan; Wanuttha Boonyayothin; Arunee Thitithanyanont; Duncan R Smith; Waranyoo Phoolcharoen
Journal:  Sci Rep       Date:  2020-10-19       Impact factor: 4.379

5.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Authors:  Merryn Voysey; Sue Ann Costa Clemens; Shabir A Madhi; Lily Y Weckx; Pedro M Folegatti; Parvinder K Aley; Brian Angus; Vicky L Baillie; Shaun L Barnabas; Qasim E Bhorat; Sagida Bibi; Carmen Briner; Paola Cicconi; Andrea M Collins; Rachel Colin-Jones; Clare L Cutland; Thomas C Darton; Keertan Dheda; Christopher J A Duncan; Katherine R W Emary; Katie J Ewer; Lee Fairlie; Saul N Faust; Shuo Feng; Daniela M Ferreira; Adam Finn; Anna L Goodman; Catherine M Green; Christopher A Green; Paul T Heath; Catherine Hill; Helen Hill; Ian Hirsch; Susanne H C Hodgson; Alane Izu; Susan Jackson; Daniel Jenkin; Carina C D Joe; Simon Kerridge; Anthonet Koen; Gaurav Kwatra; Rajeka Lazarus; Alison M Lawrie; Alice Lelliott; Vincenzo Libri; Patrick J Lillie; Raburn Mallory; Ana V A Mendes; Eveline P Milan; Angela M Minassian; Alastair McGregor; Hazel Morrison; Yama F Mujadidi; Anusha Nana; Peter J O'Reilly; Sherman D Padayachee; Ana Pittella; Emma Plested; Katrina M Pollock; Maheshi N Ramasamy; Sarah Rhead; Alexandre V Schwarzbold; Nisha Singh; Andrew Smith; Rinn Song; Matthew D Snape; Eduardo Sprinz; Rebecca K Sutherland; Richard Tarrant; Emma C Thomson; M Estée Török; Mark Toshner; David P J Turner; Johan Vekemans; Tonya L Villafana; Marion E E Watson; Christopher J Williams; Alexander D Douglas; Adrian V S Hill; Teresa Lambe; Sarah C Gilbert; Andrew J Pollard
Journal:  Lancet       Date:  2020-12-08       Impact factor: 79.321

6.  A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes.

Authors:  Tal Noy-Porat; Efi Makdasi; Ron Alcalay; Adva Mechaly; Yinon Levy; Adi Bercovich-Kinori; Ayelet Zauberman; Hadas Tamir; Yfat Yahalom-Ronen; Ma'ayan Israeli; Eyal Epstein; Hagit Achdout; Sharon Melamed; Theodor Chitlaru; Shay Weiss; Eldar Peretz; Osnat Rosen; Nir Paran; Shmuel Yitzhaki; Shmuel C Shapira; Tomer Israely; Ohad Mazor; Ronit Rosenfeld
Journal:  Nat Commun       Date:  2020-08-27       Impact factor: 14.919

7.  Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.

Authors:  Xiaolong Tian; Cheng Li; Ailing Huang; Shuai Xia; Sicong Lu; Zhengli Shi; Lu Lu; Shibo Jiang; Zhenlin Yang; Yanling Wu; Tianlei Ying
Journal:  Emerg Microbes Infect       Date:  2020-02-17       Impact factor: 7.163

8.  Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.

Authors:  Jianhui Nie; Qianqian Li; Jiajing Wu; Chenyan Zhao; Huan Hao; Huan Liu; Li Zhang; Lingling Nie; Haiyang Qin; Meng Wang; Qiong Lu; Xiaoyu Li; Qiyu Sun; Junkai Liu; Changfa Fan; Weijin Huang; Miao Xu; Youchun Wang
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

9.  Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19.

Authors:  Lauren B Rodda; Jason Netland; Laila Shehata; Kurt B Pruner; Peter A Morawski; Christopher D Thouvenel; Kennidy K Takehara; Julie Eggenberger; Emily A Hemann; Hayley R Waterman; Mitchell L Fahning; Yu Chen; Malika Hale; Jennifer Rathe; Caleb Stokes; Samuel Wrenn; Brooke Fiala; Lauren Carter; Jessica A Hamerman; Neil P King; Michael Gale; Daniel J Campbell; David J Rawlings; Marion Pepper
Journal:  Cell       Date:  2020-11-23       Impact factor: 66.850

10.  Preexisting and de novo humoral immunity to SARS-CoV-2 in humans.

Authors:  Kevin W Ng; Nikhil Faulkner; Georgina H Cornish; Annachiara Rosa; Ruth Harvey; Saira Hussain; Rachel Ulferts; Christopher Earl; Antoni G Wrobel; Donald J Benton; Chloe Roustan; William Bolland; Rachael Thompson; Ana Agua-Doce; Philip Hobson; Judith Heaney; Hannah Rickman; Stavroula Paraskevopoulou; Catherine F Houlihan; Kirsty Thomson; Emilie Sanchez; Gee Yen Shin; Moira J Spyer; Dhira Joshi; Nicola O'Reilly; Philip A Walker; Svend Kjaer; Andrew Riddell; Catherine Moore; Bethany R Jebson; Meredyth Wilkinson; Lucy R Marshall; Elizabeth C Rosser; Anna Radziszewska; Hannah Peckham; Coziana Ciurtin; Lucy R Wedderburn; Rupert Beale; Charles Swanton; Sonia Gandhi; Brigitta Stockinger; John McCauley; Steve J Gamblin; Laura E McCoy; Peter Cherepanov; Eleni Nastouli; George Kassiotis
Journal:  Science       Date:  2020-11-06       Impact factor: 47.728

View more
  13 in total

1.  Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults.

Authors:  Frances H Priddy; Michael Williams; Simon Carson; Brittany Lavender; Julia Mathieson; Chris Frampton; Nicole J Moreland; Reuben McGregor; Georgia Williams; Maia Brewerton; Katie Gell; James Ussher; Graham Le Gros
Journal:  Vaccine       Date:  2022-07-12       Impact factor: 4.169

Review 2.  Alternative Methods to Detect Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies.

Authors:  Rashmi Patel; Siddharth Khare; Vinay S Mahajan
Journal:  Clin Lab Med       Date:  2021-11-03       Impact factor: 1.935

3.  A practical approach to SARS-CoV-2 testing in a pre and post-vaccination era.

Authors:  Sean C Taylor
Journal:  J Clin Virol Plus       Date:  2021-10-08

4.  Dynamic of humoral response to SARS-CoV-2 anti-Nucleocapsid and Spike proteins after CoronaVac vaccination.

Authors:  Lucas Bochnia-Bueno; Sergio Monteiro De Almeida; Sonia Mara Raboni; Douglas Adamoski; Ludmilla Louise Moreira Amadeu; Suzana Carstensen; Meri Bordignon Nogueira
Journal:  Diagn Microbiol Infect Dis       Date:  2021-11-19       Impact factor: 2.803

5.  The Comparability of Anti-Spike SARS-CoV-2 Antibody Tests is Time-Dependent: a Prospective Observational Study.

Authors:  Thomas Perkmann; Patrick Mucher; Nicole Perkmann-Nagele; Astrid Radakovics; Manuela Repl; Thomas Koller; Klaus G Schmetterer; Johannes W Bigenzahn; Florentina Leitner; Galateja Jordakieva; Oswald F Wagner; Christoph J Binder; Helmuth Haslacher
Journal:  Microbiol Spectr       Date:  2022-02-23

6.  SARS-CoV-2 neutralizing capacity among blood donors without prior COVID-19 symptomatic history vs. blood donors with prior COVID-19 symptomatic history: A comparative study.

Authors:  Ushasree Ravula; Srinivasa Rao Chunchu; Srujaleswari Mooli; Ravi Naik; Pandu Ranga Rao Sarangapati
Journal:  Transfus Clin Biol       Date:  2022-02-12       Impact factor: 2.126

7.  Large inter-individual variability of cellular and humoral immunological responses to mRNA-1273 (Moderna) vaccination against SARS-CoV-2 in health care workers.

Authors:  Alexander Krüttgen; Gerhard Haase; Helga Haefner; Matthias Imöhl; Michael Kleines
Journal:  Clin Exp Vaccine Res       Date:  2022-01-31

8.  Comparison of the Anti-SARS-CoV-2 Surrogate Neutralization Assays by TECOmedical and DiaPROPH-Med with Samples from Vaccinated and Infected Individuals.

Authors:  Lennart Münsterkötter; Moritz Maximilian Hollstein; Andreas Hahn; Andrea Kröger; Moritz Schnelle; Luise Erpenbeck; Uwe Groß; Hagen Frickmann; Andreas Erich Zautner
Journal:  Viruses       Date:  2022-02-03       Impact factor: 5.048

9.  Performance Evaluation of the BZ COVID-19 Neutralizing Antibody Test for the Culture-Free and Rapid Detection of SARS-CoV-2 Neutralizing Antibodies.

Authors:  Bo Kyeung Jung; Jung Yoon; Joon-Yong Bae; Jeonghun Kim; Man-Seong Park; Suk Yong Lee; Chae Seung Lim
Journal:  Diagnostics (Basel)       Date:  2021-11-25

10.  Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays.

Authors:  Valentine Marie Ferré; Samuel Lebourgeois; Houssem Redha Chenane; Reyene Menidjel; Christelle Masson; Gilles Collin; Benoit Visseaux; Diane Descamps; Nadhira Fidouh; Charlotte Charpentier
Journal:  J Infect       Date:  2022-03-10       Impact factor: 38.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.